Drug intelligence / Profile preview

BioREtain Amnion Chorion

Development stage: Unknown
Lead developer: BioStem Technologies
Administration: Topical

Overview

BioREtain Amnion Chorion (BR-AC) is a placental-derived product used for wound care, particularly in treating diabetic foot ulcers and venous leg ulcers. It is processed using BioStem's proprietary BioREtain method, which preserves the natural components of the amniotic tissue, including growth factors and extracellular matrix, to support wound healing. The product is a type of allograft, made from the amnion and chorion layers of the placenta, and is applied topically to aid in wound closure.

Brand names: BR-AC
Other names: BioREtain-processed Amnion ChorionBR-AC

Beyond the preview

Go deeper on BioREtain Amnion Chorion.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BioREtain Amnion Chorion.

Explore the full profile